CompletedPhase 2NCT00006760
Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma
Studying Nodular lymphocyte predominant Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Tanya Trippett, MDMemorial Sloan Kettering Cancer Center
- Intervention
- filgrastim(biological)
- Enrollment
- 66 target
- Eligibility
- 30 years · All sexes
- Timeline
- 2001 – 2012
Study locations (30)
- Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Southern California Permanente Medical Group, Downey, California, United States
- Jonathan Jaques Children's Cancer Center at Miller Children's Hospital, Long Beach, California, United States
- Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
- Children's Hospital Central California, Madera, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Sutter Cancer Center, Sacramento, California, United States
- Kaiser Permanente Medical Center - Oakland, Sacramento, California, United States
- Children's Hospital and Health Center - San Diego, San Diego, California, United States
- Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States
- Children's Hospital Cancer Center, Denver, Colorado, United States
- Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, Connecticut, United States
- Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00006760 on ClinicalTrials.govOther trials for Nodular lymphocyte predominant Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06098430Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)St. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT05886036Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM TrialNational Cancer Institute (NCI)
See all trials for Nodular lymphocyte predominant Hodgkin lymphoma →